Israel-Medical-Healthcare

[genisi]

Can-Fite

Market cap is about $26M (97M NIS) see http://www.tase.co.il/TASEEng/General/Company/companyMainData.htm?companyID=001272&subDataType=0&shareID=01094473

how do you think their Psoriasis drug would stack up with Fumarate or if XNPT develops their "better" BG-12?

The first hurdle is beating the current cheap and well known oral drug - methotrexate on safety and efficacy. Then there are the new and advanced oral drugs in development: Pfizer's tofacitinib and CELG’s apremilast.
Fumaderm is very effective but has SE like flushing, nausea, vomiting and diarrhea in 30% of patients which typically limit the treatment period to 4-6 weeks plus it is only approved in the EU and mainly in use in Germany.